PHASE II TRIAL OF AKT INHIBITOR MK-2206 IN PATIENTS WITH ADVANCED BREAST CANCER WHO HAVE TUMORS WITH PIK3CA OR AKT MUTATIONS, AND/OR PTEN LOSS/PTEN MUTATION

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Abstract Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer.We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation.Methods The primary endpoint was objective response r

read more


Source Language and Culture Interference in Translation

The translation is a process that goes beyond linguistic transformations and demands cross-cultural awareness.However, mistakes resulting from apparently similar linguistic structures in the source and target language as well as narrow cultural views can compromise the quality of the translated text.Therefore, the target audience may lose the threa

read more